A global clinical trial, co-led by an Indian-origin researcher, has shown improved survival rates for common childhood leukemia, according to a new study.B-cell acute lymphoblastic leukemia (B-ALL) is the most common cancer in children.
A Children’s Oncology Group clinical trial led by scientists at The Hospital for Sick Children (SickKids) and Seattle Children’s Hospital has found promising results. The trial included over 200 sites across four countries.
The findings, published in the New England Journal of Medicine, showed a striking 61 per cent reduction in the risk of B-ALL relapse or death for those who received both chemotherapy and blinatumomab (an immunotherapy used for children with relapsed B-ALL).
